Company intelligence / Profile preview
Libbs Farmacêutica
- Ownership
- Private
- Employees
- ~2973
- Development stage
- Commercial
Overview
Libbs Farmacêutica has a broad commercial portfolio of approximately ninety brands across more than two hundred presentations. The company’s clinical pipeline includes combination therapies for hypertension in Phase 3 trials. Its biologics unit “Biotec” produces monoclonal antibodies and biosimilars; the company was the first to launch a locally produced biosimilar trastuzumab in Brazil[3][9][10].
- Therapeutic areas
- CardiovascularDermatologyWomen's HealthOncologyNeurology
- Modalities
- Small moleculeMonoclonal antibodyBiologic
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Libbs Farmacêutica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Libbs Farmacêutica.